Trans Tasman agency costs endanger New Zealand's minnows
This article was originally published in Clinica
New Zealand and Australia stand on the threshold of a new regulatory era with the forthcoming joint trans Tasman agency. Whilst there will be efficiencies created under the new system, Faye Sumner of the New Zealand medical devices industry association MIANZ tells Faraz Kermani in this exclusive interview that there are clearly a lot of nerves about the future for the smaller New Zealand medical devices sector.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.